In a Phase II study of relapsed or refractory FLT3/ITD‐mutated AML, the combination of sorafenib and the hypomethylating agent azacitidine yielded response rates of 46%, 36 suggesting that the combination of the two drugs may represent a clinically valuable regimen for relapsed, FLT3/ITD‐mutated AML in the elderly. Here, FLT3 is linked to acute myeloid leukemia.